Case Report

Metastatic Small-Cell Lung Cancer Presenting as Primary Adrenal Insufficiency

Shawn Esperti, Austen Stoelting, Nicolina Scibelli, David Moccia, Dveet Patel, Michael Haughton, and Andrew Mangano

Department of Internal Medicine, Grand Strand Medical Center, Myrtle Beach, SC, USA

Correspondence should be addressed to Shawn Esperti; shawn.esperti@hcahealthcare.com

Received 9 January 2020; Accepted 3 March 2020; Published 12 March 2020

Copyright © 2020 Shawn Esperti et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

A 40-year-old male smoker with HIV was admitted for cough, hypotension, and abdominal pain for 5 days. Chest radiography showed a right lower lobe consolidation. CT of the chest, abdomen, and pelvis revealed paratracheal adenopathy, a 5.8 × 4.5 cm mass invading the right bronchus intermedius, and dense bilateral adrenal masses, measuring 5.4 × 4.0 cm on the right and 4.8 × 2.0 cm on the left. Laboratory studies showed white blood cell count of 18.5 K/mm³, sodium of 131 mmol/L, creatinine of 1.6 mg/dL, and CD4 count of 567 cells/mm³. The random morning cortisol level was 7.0 μg/dL, the ACTH stimulation test yielded inappropriate response, and a random serum ACTH was elevated at 83.4 pg/mL. MRI brain revealed no pituitary adenoma confirming primary adrenal insufficiency. The adrenal CT washout study was consistent with solid mass content, concerning for metastasis. Bronchoscopy with endobronchial mass and paratracheal lymph node biopsy confirmed small-cell lung cancer (SCLC). Intravenous steroids, 100 mg hydrocortisone every 8 hours, improved his hypotension and abdominal pain. PET scan revealed metabolically active right paratracheal mass, right hilar mass, and bilateral adrenal masses. Treatment included palliative chemotherapy consisting of carboplatin/etoposide/atezolizumab and chest radiation.

We present this novel case to demonstrate SCLC’s ability to cause primary adrenal insufficiency, as well as evaluate clinical response to chemotherapeutics.

1. Introduction

Small-cell lung cancer (SCLC) is a neuroendocrine tumor highly associated with heavy tobacco use and represents about 15% of all primary lung cancers [1]. It is recognized as the most rapidly progressive lung cancer, with up to 60% of cases with metastatic disease at the time of diagnosis [2]. SCLC is distinguished from non-small-cell lung cancers due to its rapid mitotic rate with median survival of approximately 2–4 months when untreated and a 5-year survival rate in the range of 4%–5% when treated [3]. The most common sites of distant metastases are the liver, bone, brain, lung, and adrenal gland, respectively [3]. Although adrenal metastases comprise 6% of all SCLC metastases, there has been only one case report of primary adrenal insufficiency resulting from SCLC metastasis published to date [4]. We present this case to demonstrate SCLC’s aggressive nature and ability to cause primary adrenal insufficiency with extensive bilateral adrenal metastases. We will also examine this patient’s clinical response to chemotherapeutic agents.

2. Case Report

A 40-year-old male with a past medical history of tobacco abuse and HIV presented to our hospital for cough, nausea, vomiting, and abdominal pain of 5-day duration. Upon arrival, the patient was afebrile, with a pulse rate of 104 and a blood pressure of 80/60. Chest radiography revealed a right lower lobe consolidation. Chest CT revealed right paratracheal adenopathy and a 5.8 × 4.5 cm mass occluding the bronchus intermedius (Figure 1(a)). CT of the abdomen and pelvis without contrast revealed dense bilateral adrenal masses, measuring 5.4 × 4.0 cm on the right and 4.8 × 2.0 cm on the left (Figure 2(a)). Laboratory studies were significant for a white blood cell count of 18.5 K/mm³, sodium of 131 mmol/L, creatinine of 1.6 mg/dL, and CD4 count of 567 cells/mm³. Due
Figure 1: (a) Chest CT without contrast prior to chest radiation showing a $5.8 \times 4.5$ cm right infra hilar mass obstructing the bronchus intermedius with right paratracheal adenopathy. Postobstructive consolidation of the right lower lobe and patchy infiltration of the right middle lobe. (b) Chest CT with IV contrast postchest radiation revealing significant improvement in the right hilar lesion. There is slight thickening around the right main bronchus; the large soft tissue lesion has almost totally resolved with resolution of postobstructive changes.

Figure 2: (a) CT abdomen and pelvis with IV contrast showing bilateral adrenal masses with the right measuring $5.4 \times 4.0$ cm and the left measuring $4.8 \times 2.0$ cm, highly concerning for metastatic disease. Arrows pointing to adrenal masses. (b) PET CT prior to chemotherapy showing metabolically active right hilar mass, metabolically active right paratracheal lymphadenopathy, decreased prominence of mediastinal adenopathy, and metabolically active bilateral adrenal masses consistent with metastatic disease. (c) CT abdomen and pelvis with PO and IV contrast demonstrates that both adrenal glands have significantly decreased in size, measuring $2.9 \times 1.6$ cm on the left and $3.4 \times 2.0$ cm on the right. Arrows pointing to adrenal masses. (d) CT of the chest revealing near-total resolution of the right hilar mass without postobstruction.
The patient finished his final two cycles of chemotherapy and transitioned to maintenance atezolizumab. At two months of maintenance therapy follow-up staging, CT scan revealed a mixed response to therapy. The right adrenal mass increased from $3.4 \times 2.0 \text{ cm}$ to $4.3 \times 2.9 \text{ cm}$ with more irregular margins. The left adrenal mass increased from $2.9 \times 1.6 \text{ cm}$ to $3.9 \times 2.0 \text{ cm}$ (Figure 4) while the right lung soft tissue mass continued to decrease from $1.0 \times 0.6 \text{ cm}$ to $0.8 \times 0.8 \text{ cm}$. After treatment failure, the patient was transitioned to hospice care.

3. Discussion

The adrenal glands have a rich sinusoidal blood supply providing a conduit for infection and metastasis [5]. Bilateral adrenal metastases at the time of diagnosis are found in 3% of SCLC patients [6], but many other etiologies must be considered. The differential diagnosis for bilateral adrenal masses remains broad and includes a spectrum of disorders including infectious causes, neoplastic causes, endocrinopathies, or even traumatic causes [7]. Infectious etiologies include mycobacterial and fungal infections. Disseminated mycobacterial tuberculosis, histoplasmosis, and blastomycosis have been reported frequently, and parasitic infections remain rare [8]. Metastasis is the most common malignancy, but also lymphoma, bilateral pheochromocytoma, adrenocortical carcinomas, and myelolipomas have presented as bilateral adrenal masses [9]. Long-standing uncontrolled congenital adrenal hyperplasia and macronodular hyperplasia are endocrine disorders that can present as bilateral adrenal masses [10]. Bilateral adrenal hemorrhage should be considered especially in the setting of trauma, sepsis with vasopressor usage, antiphospholipid syndrome, and the use of anticoagulants [11].

Once primary adrenal insufficiency was diagnosed with a low morning cortisol, elevated ACTH, inappropriate ACTH stimulation test, and MRI showing no central lesion, the adrenal masses were the likely etiology. Without any upper lobe densities and negative infectious workup, tuberculosis and fungal infection were unlikely. CT of the abdomen and pelvis revealed bilateral masses without evidence of necrosis or abscess that would suggest adrenal hemorrhage or

![Figure 3: (a) Direct smears and thin prep revealing carcinoma in a neuroendocrine pattern of poorly cohesive cells with increased nuclear to cytoplasmic ratio with salt-and-pepper nuclei and nuclear molding of endobronchial mass tissue. (b) Direct smears and thin prep at high magnification revealing the same results of 4R lymph node biopsy.](image)
infection. With a normal serum renin : aldosterone ratio and plasma metanephrines, functional adenoma and pheochromocytoma were ruled out. The adrenal CT washout study did not demonstrate any significant density changes consistent with solid metastatic disease. Once endobronchial biopsy of the right hilar mass and paratracheal nodes showed SCLC, coupled with increased adrenal gland metabolic activity on PET scan, it was reasonable to presume the adrenal masses were SCLC.

Although lung cancer does metastasize to the adrenal gland, adrenal insufficiency is rare, as greater than 90% of the functional cortex must be destroyed for this to occur [12]. In one retrospective study spanning 30 years with 464 patients with adrenal metastatic disease from various tumors, only five of these patients developed adrenal insufficiency [13]. Primary adrenal insufficiency in the setting of SCLC has been reported only in one case report in Japan [4]. This case highlights the aggressive potential of SCLC in a novel fashion. SCLC was able to obliterate the adrenal glands, by exploiting the body’s vascular network for dissemination and nourishment for rapid growth.

4. Conclusion

Although exceedingly rare, metastatic SCLC should be considered in the differential diagnoses for primary adrenal insufficiency in patients with risk factors such as tobacco abuse and HIV. This case demonstrates the aggressive nature of SCLC, and its potential to cause significant adrenal tissue destruction leading to primary adrenal insufficiency.

Disclosure

The views expressed in this publication represent those of the authors and do not necessarily represent the official views of HCA Healthcare or any of its affiliated entities.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Acknowledgments

This research was supported (in whole or in part) by HCA Healthcare and/or an HCA Healthcare-affiliated entity.

References

[1] G. P. Kalemkerian, W. Akerley, P. Bogner et al., “Small cell lung cancer,” Journal of the National Comprehensive Cancer Network, vol. 11, no. 1, pp. 78–98, 2013.
[2] E. B. Bernhardt and S. I. Jalal, “Small cell lung cancer,” in Lung Cancer, Cancer Treatment and Research, K. Reckamp, Ed., vol. 170, pp. 301–322, Springer, Cham, 2016.
[3] T. Tamura, K. Kurishima, K. Nakazawa et al., “Specific organ metastases and survival in metastatic non-small-cell lung cancer,” Molecular and Clinical Oncology, vol. 3, no. 1, pp. 217–221, 2015.
[4] S. Noguchi, R. Torii, I. Shimabukuro et al., “Adrenal insufficiency associated with small cell lung cancer: a case report and literature review,” Journal of UOEH, vol. 38, no. 2, pp. 155–162, 2016.
[5] K. Plichte, N. Camden, M. Furqan et al., “SBRT to adrenal metastases provides high local control with minimal toxicity,” Advances in radiation oncology, vol. 2, no. 4, pp. 581–587, 2017.
[6] N. Singh, K. Madan, A. Aggarwal, and A. Das, “Symptomatic large bilateral adrenal metastases at presentation in small-cell lung cancer: a case report and review of the literature,” Journal of Thoracic Disease, vol. 5, p. E83, 2013.
[7] P. Gupta, A. Bhalla, and R. Sharma, “Bilateral adrenal lesions,” Journal of Medical Imaging and Radiation Oncology, vol. 56, no. 6, pp. 636–645, 2012.
[8] W. F. Paolo Jr. and J. D. Nosanchuk, “Adrenal infections,” International Journal of Infectious Diseases, vol. 10, no. 5, pp. 343–353, 2006.
[9] J. Zhou, D. Ye, M. Wu et al., “Bilateral adrenal tumor: causes and clinical features in eighteen cases,” International Urology and Nephrology, vol. 41, no. 3, pp. 547–551, 2008.
[10] L. K. Nieman, “9. Patient with an adrenal incidentaloma,” in A Clinical Approach to Endocrine & Metabolic Diseases, pp. 120–132, 2012.
[11] Z. Fatima, U. Tariq, A. Khan et al., “A rare case of bilateral adrenal hemorrhage,” Cureus, vol. 10, article e2830, 2018.
[12] F. Carvalho, F. Louro, and R. Zakout, “Adrenal insufficiency in metastatic lung cancer,” World journal of oncology, vol. 6, no. 3, pp. 375–377, 2015.
[13] K. Harris, I. Khachaturova, B. Azab et al., “Small cell lung cancer doubling time and its effect on clinical presentation: a concise review,” Clinical Medicine Insights Oncology, vol. 6, pp. CMO.S9633–CMO.S9203, 2012.